Sign In
Buy ADMA
$8.69
+0.120 (+1.40%)
At Close: Jun 23, 2026
ADMA Biologics: Sell-Off Provides Buying Opportunity Ahead Of Projected Growth
10:13pm, Wednesday, 07'th Apr 2021
ADMA Biologics recently reported a mixed Q4/2020 earnings with a slight miss on EPS and a slight beat on revenue. Consequently, ADMA has been under substantial selling pressure. The ongoing pandemic h
ADMA Biologics: Continuing To Execute
06:34pm, Tuesday, 06'th Apr 2021
ADMA continues to execute and delivered another great quarter. ADMA has improved its guidance with respect to profitability and plasma center developments.
ADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q4 2020 Results - Earnings Call Transcript
10:26pm, Thursday, 25'th Mar 2021
ADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q4 2020 Results - Earnings Call Transcript
Adma Biologics (ADMA) Reports Q4 Loss, Tops Revenue Estimates
06:11pm, Thursday, 25'th Mar 2021
Adma Biologics (ADMA) delivered earnings and revenue surprises of -17.65% and 0.40%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
ADMA Biologics Reports Fourth Quarter and Full Year 2020 Financial Results
04:05pm, Thursday, 25'th Mar 2021
Achieved Full Year 2020 Total Revenues of $42.2 Million, a 44% Increase Over Full Year 2019
ADMA Biologics to Participate in the Jefferies Virtual Plasma Summit
08:00am, Thursday, 04'th Mar 2021
RAMSEY, N.J. and BOCA RATON, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicate
4 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates
09:05am, Friday, 19'th Feb 2021
Let us take a look at some drug/biotech stocks that are poised to beat on fourth-quarter earnings.
Adma Biologics (ADMA) Upgraded to Buy: Here's Why
12:53pm, Wednesday, 17'th Feb 2021
Adma Biologics (ADMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2020 Revenues and Provides 2021 Strategic Outlook
08:00am, Tuesday, 19'th Jan 2021
Achieved Fourth Quarter 2020 Preliminary Unaudited Total Revenues of $13.9 Million, the Highest Revenue Quarter for the Company Since Inception
ADMA Biologics: A Perfect Storm
12:47am, Tuesday, 05'th Jan 2021
ADMA has been overly chastised by the market, and its business is performing very well. At its current trading level, ADMA is trading at just about its enterprise value when considering the value of i
ADMA Biologics Receives Unique Temporary C-Code and Pass-Through Payment Status for ASCENIV™
08:00am, Monday, 04'th Jan 2021
RAMSEY, N.J. and BOCA RATON, Fla., Jan. 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and d
ADMA Biologics Adopts Limited Duration Stockholder Rights Plan
04:15pm, Wednesday, 16'th Dec 2020
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 16, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and d
ADMA Biologics (ADMA) in Focus: Stock Moves 6.6% Higher
08:48am, Wednesday, 09'th Dec 2020
ADMA Biologics (ADMA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
ADMA Biologics: Another Quarter Of Progress And Another Dip To Buy
10:07pm, Wednesday, 11'th Nov 2020
ADMA Biologics recently reported its Q3 earnings with a beat on EPS and revenue. In addition, the company reported encouraging commercial progress for its IVIG products despite the COVID-19 headwinds.
ADMA Biologics to Participate in Jefferies 2020 Virtual London Healthcare Conference
07:00am, Tuesday, 10'th Nov 2020
RAMSEY, N.J. and BOCA RATON, Fla., Nov. 10, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated
